Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 19, 2017 08:24 ET | Source: Albireo, Inc.

Albireo to Present at Investor Conferences in September

BOSTON, Sept. 19, 2017 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Ron...
September 05, 2017 08:00 ET | Source: Albireo, Inc.

Albireo to Present at 19th Annual Rodman & Renshaw Global Investment Conference

BOSTON, Sept. 05, 2017 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that...
August 21, 2017 08:36 ET | Source: Albireo, Inc.

Albireo Reports Second Quarter 2017 Financial Results

— Plans to initiate A4250 Phase 3 trial by year end — — Following successful equity financing in May, cash runway expected through at least 2019 — BOSTON, Aug. 21, 2017 (GLOBE NEWSWIRE) -- Albireo...
August 08, 2017 08:00 ET | Source: Albireo, Inc.

Albireo to Present at Wedbush PacGrow Healthcare Conference

BOSTON, Aug. 08, 2017 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Ron...
May 30, 2017 16:01 ET | Source: Albireo, Inc.

Albireo Announces Closing of $51.9 Million Public Offering Including Exercise of Underwriters’ Option to Purchase Additional Shares

BOSTON, May 30, 2017 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (NASDAQ:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today the...
May 24, 2017 08:38 ET | Source: Albireo, Inc.

Albireo Prices $45.1 Million Public Offering of Common Stock

BOSTON, May 24, 2017 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (NASDAQ:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today the...
May 23, 2017 16:01 ET | Source: Albireo, Inc.

Albireo Announces Proposed Public Offering of Common Stock

BOSTON, May 23, 2017 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (NASDAQ:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today that it...
May 18, 2017 08:00 ET | Source: Albireo, Inc.

Albireo Announces Plans for Phase 3 Clinical Program of A4250 in Patients with PFIC

— Program design finalized following consultations with FDA and EMA — — Initiation of Phase 3 anticipated in the second half of 2017 — BOSTON, May 18, 2017 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc....
May 16, 2017 08:00 ET | Source: Albireo, Inc.

Albireo Announces Two New U.S. Patents Allowed for A4250 with Term into 2031

BOSTON, May 16, 2017 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that the...
May 10, 2017 16:01 ET | Source: Albireo, Inc.

Albireo Reports First Quarter 2017 Financial Results

BOSTON, May 10, 2017 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (NASDAQ:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today reported its...